The Molecular Determinants of NEDD8 Specific Recognition by Human SENP8
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
1 Isolation and Characterization of Cul1-7, a Recessive Allele Of
Genetics: Published Articles Ahead of Print, published on February 25, 2009 as 10.1534/genetics.108.097675 Isolation and Characterization of cul1-7, a Recessive Allele of CULLIN1 that Disrupts SCF Function at the C-terminus of CUL1 in Arabidopsis thaliana Jonathan Gilkerson*,†, Jianhong Hu‡, Jessica Brown*, Alexander Jones* 1, Tai-ping Sun‡ and Judy Callis*,†,2 *Department of Molecular and Cellular Biology and †Plant Biology Graduate Group, University of California-Davis, Davis, CA 95616, ‡Department of Biology, Duke University, Durham, North Carolina 27708-1000 1 Current Address: Department of Plant and Microbial Biology, UC-Berkeley, Berkeley, CA 94720-3102 1 Running head: Characterization of cul1-7 Key words: Protein Degradation, Aux/IAA, RGA, SCF Ubiquitin Ligase, RBX1 2Corresponding Author: Judy Callis Department of Molecular and Cellular Biology University of California-Davis One Shields Avenue Davis, CA 95616 Phone: 530-752-1015 Fax: 530-752-3085 E-mail: [email protected] 2 ABSTRACT Many aspects of plant biology depend on the ubiquitin proteasome system for degradation of regulatory proteins. Ubiquitin E3 ligases confer substrate specificity in this pathway, and SCF-type ligases comprise a major class of E3s. SCF ligases have four subunits: SKP1, CUL1, RBX1, and an F-box protein for substrate recognition. The Aux/IAAs are a well- characterized family of SCF substrates in plants. Here, we report characterization of a mutant isolated from a genetic screen in Arabidopsis thaliana designed to identify plants defective in degradation of an Aux/IAA fusion protein, Aux/IAA1-luciferase (IAA1-LUC). This mutant exhibited four-fold slower IAA1-LUC degradation compared to the progenitor line, and seedlings displayed altered auxin responses. -
Vascular Inflammatory Response Deneddylase-1/SENP8 in Fine
Central Role for Endothelial Human Deneddylase-1/SENP8 in Fine-Tuning the Vascular Inflammatory Response This information is current as Stefan F. Ehrentraut, Douglas J. Kominsky, Louise E. of September 30, 2021. Glover, Eric L. Campbell, Caleb J. Kelly, Brittelle E. Bowers, Amanda J. Bayless and Sean P. Colgan J Immunol 2013; 190:392-400; Prepublished online 3 December 2012; doi: 10.4049/jimmunol.1202041 Downloaded from http://www.jimmunol.org/content/190/1/392 Supplementary http://www.jimmunol.org/content/suppl/2012/12/03/jimmunol.120204 Material 1.DC1 http://www.jimmunol.org/ References This article cites 53 articles, 15 of which you can access for free at: http://www.jimmunol.org/content/190/1/392.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 30, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Central Role for Endothelial Human Deneddylase-1/SENP8 in Fine-Tuning the Vascular Inflammatory Response Stefan F. -
Neddylation: a Novel Modulator of the Tumor Microenvironment Lisha Zhou1,2*†, Yanyu Jiang3†, Qin Luo1, Lihui Li1 and Lijun Jia1*
Zhou et al. Molecular Cancer (2019) 18:77 https://doi.org/10.1186/s12943-019-0979-1 REVIEW Open Access Neddylation: a novel modulator of the tumor microenvironment Lisha Zhou1,2*†, Yanyu Jiang3†, Qin Luo1, Lihui Li1 and Lijun Jia1* Abstract Neddylation, a post-translational modification that adds an ubiquitin-like protein NEDD8 to substrate proteins, modulates many important biological processes, including tumorigenesis. The process of protein neddylation is overactivated in multiple human cancers, providing a sound rationale for its targeting as an attractive anticancer therapeutic strategy, as evidence by the development of NEDD8-activating enzyme (NAE) inhibitor MLN4924 (also known as pevonedistat). Neddylation inhibition by MLN4924 exerts significantly anticancer effects mainly by triggering cell apoptosis, senescence and autophagy. Recently, intensive evidences reveal that inhibition of neddylation pathway, in addition to acting on tumor cells, also influences the functions of multiple important components of the tumor microenvironment (TME), including immune cells, cancer-associated fibroblasts (CAFs), cancer-associated endothelial cells (CAEs) and some factors, all of which are crucial for tumorigenesis. Here, we briefly summarize the latest progresses in this field to clarify the roles of neddylation in the TME, thus highlighting the overall anticancer efficacy of neddylaton inhibition. Keywords: Neddylation, Tumor microenvironment, Tumor-derived factors, Cancer-associated fibroblasts, Cancer- associated endothelial cells, Immune cells Introduction Overall, binding of NEDD8 molecules to target proteins Neddylation is a reversible covalent conjugation of an can affect their stability, subcellular localization, conform- ubiquitin-like molecule NEDD8 (neuronal precursor ation and function [4]. The best-characterized substrates cell-expressed developmentally down-regulated protein of neddylation are the cullin subunits of Cullin-RING li- 8) to a lysine residue of the substrate protein [1, 2]. -
Inhibition of SCF Ubiquitin Ligases by Engineered Ubiquitin Variants That Target the Cul1 Binding Site on the Skp1–F-Box Interface
Inhibition of SCF ubiquitin ligases by engineered ubiquitin variants that target the Cul1 binding site on the Skp1–F-box interface Maryna Gorelika,b, Stephen Orlickyc, Maria A. Sartoria,b, Xiaojing Tangc, Edyta Marcona,b, Igor Kurinovd, Jack F. Greenblatta,b, Mike Tyersc,e, Jason Moffata,b, Frank Sicheric,f, and Sachdev S. Sidhua,b,1 aBanting and Best Department of Medical Research, Terrence Donnelly Center for Cellular and Biomolecular Research, University of Toronto, Toronto, ON, Canada M5S 3E1; bDepartment of Molecular Genetics, Terrence Donnelly Center for Cellular and Biomolecular Research, University of Toronto, Toronto, ON, Canada M5S 3E1; cLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada M5G 1X5; dDepartment of Chemistry and Chemical Biology, Cornell University, Argonne, IL 60439; eInstitut de Recherche en Immunologie et Cancérologie, Université de Montréal, Montreal, QC, Canada H3C 3J7; and fDepartment of Molecular Genetics, University of Toronto, Toronto, ON, Canada M5S 3E1 Edited by Mark Estelle, University of California, San Diego, La Jolla, CA, and approved February 17, 2016 (received for review October 14, 2015) Skp1–Cul1–F-box (SCF) E3 ligases play key roles in multiple cellular are subdivided into three subfamilies based on the structure of processes through ubiquitination and subsequent degradation of their substrate binding domains, including WD40, LRR, and substrate proteins. Although Skp1 and Cul1 are invariant compo- other domains, referred to as the Fbw, Fbl, and Fbo subfamilies, nents of all SCF complexes, the 69 different human F-box proteins respectively (3). are variable substrate binding modules that determine specificity. Numerous F-box proteins are involved in processes relevant to SCF E3 ligases are activated in many cancers and inhibitors could tumorigenesis, including cell proliferation, cell cycle progression, have therapeutic potential. -
Mouse Cul1 Conditional Knockout Project (CRISPR/Cas9)
https://www.alphaknockout.com Mouse Cul1 Conditional Knockout Project (CRISPR/Cas9) Objective: To create a Cul1 conditional knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Cul1 gene (NCBI Reference Sequence: NM_012042 ; Ensembl: ENSMUSG00000029686 ) is located on Mouse chromosome 6. 22 exons are identified, with the ATG start codon in exon 2 and the TAA stop codon in exon 22 (Transcript: ENSMUST00000031697). Exon 5~6 will be selected as conditional knockout region (cKO region). Deletion of this region should result in the loss of function of the Mouse Cul1 gene. To engineer the targeting vector, homologous arms and cKO region will be generated by PCR using BAC clone RP23-18I21 as template. Cas9, gRNA and targeting vector will be co-injected into fertilized eggs for cKO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Homozygotes for targeted null mutations accumulate cyclin E1 and exhibit arrested development and lethality around embryonic day 6.5. Exon 5 starts from about 20.79% of the coding region. The knockout of Exon 5~6 will result in frameshift of the gene. The size of intron 4 for 5'-loxP site insertion: 3779 bp, and the size of intron 6 for 3'-loxP site insertion: 637 bp. The size of effective cKO region: ~1122 bp. The cKO region does not have any other known gene. Page 1 of 8 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele 5' gRNA region gRNA region 3' 1 5 6 7 22 Targeting vector Targeted allele Constitutive KO allele (After Cre recombination) Legends Exon of mouse Cul1 Homology arm cKO region loxP site Page 2 of 8 https://www.alphaknockout.com Overview of the Dot Plot Window size: 10 bp Forward Reverse Complement Sequence 12 Note: The sequence of homologous arms and cKO region is aligned with itself to determine if there are tandem repeats. -
A Systems-Wide Screen Identifies Substrates of the SCF Ubiquitin Ligase
RESEARCH RESOURCE PROTEOMICS A systems-wide screen identifies substrates of the SCFbTrCP ubiquitin ligase Teck Yew Low,1,2 Mao Peng,1,2* Roberto Magliozzi,3* Shabaz Mohammed,1,2† Daniele Guardavaccaro,3 Albert J. R. Heck1,2‡ Cellular proteins are degraded by the ubiquitin-proteasome system (UPS) in a precise and timely fashion. Such precision is conferred by the high substrate specificity of ubiquitin ligases. Identification of substrates of ubiquitin ligases is crucial not only to unravel the molecular mechanisms by which the UPS controls protein degradation but also for drug discovery purposes because many established UPS substrates are implicated in disease. We developed a combined bioinformatics and affinity purification– mass spectrometry (AP-MS) workflow for the system-wide identification of substrates of SCFbTrCP,a member of the SCF family of ubiquitin ligases. These ubiquitin ligases are characterized by a multi- subunit architecture typically consisting of the invariable subunits Rbx1, Cul1, and Skp1, and one of 69 F-box proteins. The F-box protein of this member of the family is bTrCP. SCFbTrCP binds, through the WD40 b repeats of TrCP, to the DpSGXX(X)pS diphosphorylated motif in its substrates. We recovered 27 pre- Downloaded from viously reported SCFbTrCP substrates, of which 22 were verified by two independent statistical proto- cols, thereby confirming the reliability of this approach. In addition to known substrates, we identified 221 proteins that contained the DpSGXX(X)pS motif and also interacted specifically with the WD40 repeats of bTrCP. Thus, with SCFbTrCP, as the example, we showed that integration of structural infor- mation, AP-MS, and degron motif mining constitutes an effective method to screen for substrates of ubiquitin ligases. -
Cyclin F-Chk1 Synthetic Lethality Mediated by E2F1 Degradation
bioRxiv preprint doi: https://doi.org/10.1101/509810; this version posted January 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Cyclin F-Chk1 synthetic lethality mediated by E2F1 degradation Kamila Burdova1, Hongbin Yang1, Roberta Faedda1, Samuel Hume1, Daniel Ebner2, Benedikt M Kessler2, Iolanda Vendrell1,2, David H Drewry3, Carrow I Wells3, Stephanie B Hatch2, Vincenzo D’Angiolella1* 1Medical Research Council Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK 2Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7FZ, UK 3Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America * Corresponding Author: [email protected] Summary Cyclins are central engines of cell cycle progression when partnered with Cyclin Dependent Kinases (CDKs). Among the different cyclins controlling cell cycle progression, cyclin F does not partner with a CDK, but forms an E3 ubiquitin ligase, assembling through the F-box domain, an Skp1-Cul1-F-box (SCF) module. Although multiple substrates of cyclin F have been identified the vulnerabilities of cells lacking cyclin F are not known. Thus, we assessed viability of cells lacking cyclin F upon challenging cells with more than 200 kinase inhibitors. The screen revealed a striking synthetic lethality between Chk1 inhibition and cyclin F loss. -
8P23.2-Pter Microdeletions: Seven New Cases Narrowing the Candidate Region and Review of the Literature
G C A T T A C G G C A T genes Article 8p23.2-pter Microdeletions: Seven New Cases Narrowing the Candidate Region and Review of the Literature Ilaria Catusi 1,* , Maria Garzo 1 , Anna Paola Capra 2 , Silvana Briuglia 2 , Chiara Baldo 3 , Maria Paola Canevini 4 , Rachele Cantone 5, Flaviana Elia 6, Francesca Forzano 7, Ornella Galesi 8, Enrico Grosso 5, Michela Malacarne 3, Angela Peron 4,9,10 , Corrado Romano 11 , Monica Saccani 4 , Lidia Larizza 1 and Maria Paola Recalcati 1 1 Istituto Auxologico Italiano, IRCCS, Laboratory of Medical Cytogenetics and Molecular Genetics, 20145 Milan, Italy; [email protected] (M.G.); [email protected] (L.L.); [email protected] (M.P.R.) 2 Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, 98100 Messina, Italy; [email protected] (A.P.C.); [email protected] (S.B.) 3 UOC Laboratorio di Genetica Umana, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy; [email protected] (C.B.); [email protected] (M.M.) 4 Child Neuropsychiatry Unit—Epilepsy Center, Department of Health Sciences, ASST Santi Paolo e Carlo, San Paolo Hospital, Università Degli Studi di Milano, 20142 Milan, Italy; [email protected] (M.P.C.); [email protected] (A.P.); [email protected] (M.S.) 5 Medical Genetics Unit, Città della Salute e della Scienza University Hospital, 10126 Turin, Italy; [email protected] (R.C.); [email protected] (E.G.) 6 Unit of Psychology, Oasi Research Institute-IRCCS, -
Potential Sperm Contributions to the Murine Zygote Predicted by in Silico Analysis
REPRODUCTIONRESEARCH Potential sperm contributions to the murine zygote predicted by in silico analysis Panagiotis Ntostis1,2, Deborah Carter3, David Iles1, John Huntriss1, Maria Tzetis2 and David Miller1 1Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, West Yorkshire, UK, 2Department of Medical Genetics, St. Sophia’s Children Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Attiki, Greece and 3Leeds Institute of Molecular Medicine, University of Leeds, Leeds, West Yorkshire, UK Correspondence should be addressed to D Miller; Email: [email protected] Abstract Paternal contributions to the zygote are thought to extend beyond delivery of the genome and paternal RNAs have been linked to epigenetic transgenerational inheritance in different species. In addition, sperm–egg fusion activates several downstream processes that contribute to zygote formation, including PLC zeta-mediated egg activation and maternal RNA clearance. Since a third of the preimplantation developmental period in the mouse occurs prior to the first cleavage stage, there is ample time for paternal RNAs or their encoded proteins potentially to interact and participate in early zygotic activities. To investigate this possibility, a bespoke next-generation RNA sequencing pipeline was employed for the first time to characterise and compare transcripts obtained from isolated murine sperm, MII eggs and pre-cleavage stage zygotes. Gene network analysis was then employed to identify potential interactions between paternally and maternally derived factors during the murine egg-to-zygote transition involving RNA clearance, protein clearance and post-transcriptional regulation of gene expression. Our in silico approach looked for factors in sperm, eggs and zygotes that could potentially interact co-operatively and synergisticallyp during zygote formation. -
Anti-BTRC / Beta Trcp1 Antibody (ARG57309)
Product datasheet [email protected] ARG57309 Package: 100 μl anti-BTRC / beta TrCP1 antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes BTRC / beta TrCP1 Tested Reactivity Hu Tested Application IHC-P, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name BTRC / beta TrCP1 Antigen Species Human Immunogen Recombinant Protein of Human BTRC / beta-TrCP1. Conjugation Un-conjugated Alternate Names bTrCP1; betaTrCP; BETA-TRCP; FBW1A; Epididymis tissue protein Li 2a; F-box and WD repeats protein beta-TrCP; E3RSIkappaB; pIkappaBalpha-E3 receptor subunit; FBXW1A; FWD1; bTrCP; FBXW1; F- box/WD repeat-containing protein 1A Application Instructions Application table Application Dilution IHC-P 1:50 - 1:200 WB 1:500 - 1:2000 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Positive Control BT474 Calculated Mw 69 kDa Properties Form Liquid Purification Affinity purification with immunogen. Buffer PBS (pH 7.3), 0.02% Sodium azide and 50% Glycerol. Preservative 0.02% Sodium azide Stabilizer 50% Glycerol Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. www.arigobio.com 1/3 Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Gene Symbol BTRC Gene Full Name beta-transducin repeat containing E3 ubiquitin protein ligase Background This gene encodes a member of the F-box protein family which is characterized by an approximately 40 amino acid motif, the F-box. -
Neddylation Regulates Class Iia and III Histone Deacetylases to Mediate Myoblast Differentiation
International Journal of Molecular Sciences Article Neddylation Regulates Class IIa and III Histone Deacetylases to Mediate Myoblast Differentiation Hongyi Zhou 1,* , Huabo Su 2 and Weiqin Chen 1 1 Department of Physiology, Medical College of Georgia at Augusta University, Augusta, GA 30912, USA; [email protected] 2 Vascular Biology Center, Medical College of Georgia at Augusta University, Augusta, GA 30912, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-706-721-8779 Abstract: As the largest tissue in the body, skeletal muscle has multiple functions in movement and energy metabolism. Skeletal myogenesis is controlled by a transcriptional cascade including a set of muscle regulatory factors (MRFs) that includes Myogenic Differentiation 1 (MYOD1), Myocyte En- hancer Factor 2 (MEF2), and Myogenin (MYOG), which direct the fusion of myogenic myoblasts into multinucleated myotubes. Neddylation is a posttranslational modification that covalently conjugates ubiquitin-like NEDD8 (neural precursor cell expressed, developmentally downregulated 8) to protein targets. Inhibition of neddylation impairs muscle differentiation; however, the underlying molec- ular mechanisms remain less explored. Here, we report that neddylation is temporally regulated during myoblast differentiation. Inhibition of neddylation through pharmacological blockade using MLN4924 (Pevonedistat) or genetic deletion of NEDD8 Activating Enzyme E1 Subunit 1 (NAE1), a subunit of the E1 neddylation-activating enzyme, blocks terminal myoblast differentiation par- tially through repressing MYOG expression. Mechanistically, we found that neddylation deficiency enhances the mRNA and protein expressions of class IIa histone deacetylases 4 and 5 (HDAC4 Citation: Zhou, H.; Su, H.; Chen, W. and 5) and prevents the downregulation and nuclear export of class III HDAC (NAD-Dependent Neddylation Regulates Class IIa and Protein Deacetylase Sirtuin-1, SIRT1), all of which have been shown to repress MYOD1-mediated III Histone Deacetylases to Mediate MYOG transcriptional activation. -
Genome-Wide CRISPR Screens Reveal Genetic Mediators of Cereblon Modulator Toxicity in Primary Effusion Lymphoma
bioRxiv preprint doi: https://doi.org/10.1101/619312; this version posted April 25, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Genome-wide CRISPR Screens Reveal Genetic Mediators of Cereblon Modulator Toxicity in Primary Effusion Lymphoma Ajinkya Patil1, Mark Manzano1, and Eva Gottwein1 1Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, 60611 USA. Short Title: Cereblon Modulator Resistance Screens in PEL Corresponding Author: Eva Gottwein Department of Microbiology-Immunology Northwestern University Feinberg School of Medicine 320 E Superior St., Tarry Bldg., Room 6-735 Chicago, Illinois 60611 USA e-mail address: [email protected] Phone: +1-312-503-3075 Fax: +1-312-503-5101 Word Count Text: 3986 Word Count Abstract: 250 Figure Count: 7 main figures, 8 supplementary figures Table Count: 0 main manuscript, 8 supplementary tables Reference Count: 43 Scientific Category: Lymphoid Neoplasia 1 bioRxiv preprint doi: https://doi.org/10.1101/619312; this version posted April 25, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Genome-wide CRISPR/Cas9 screens represent a powerful approach to study mechanisms of drug action and resistance. Cereblon modulating agents (CMs) have recently emerged as candidates for therapeutic intervention in primary effusion lymphoma (PEL), a highly aggressive cancer caused by Kaposi’s sarcoma-associated herpesvirus. CMs bind to cereblon (CRBN), the substrate receptor of the cullin-RING type E3 ubiquitin ligase CRL4CRBN, and thereby trigger the acquisition and proteasomal degradation of neosubstrates.